Bioceres Crop Solutions Corp. (BIOX) AI Stock Analysis

Headquartered in Rosario, Argentina, Bioceres Crop Solutions Corp. develops and commercializes agricultural productivity technologies worldwide. The business operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. Seed and Integrated Products offers germplasms, seed treatment packs, and seed traits such as the HB4 drought-tolerant technology. Crop Protection develops and markets biological and chemical treatments, including Rizoderma, adjuvants, therapies, herbicides, insecticides, and fungicides. Crop Nutrition commercializes inoculants, bio-inductors, and biological and microgranulated fertilizers to enhance soil fertility and crop nutrient uptake across markets including Argentina, Brazil, and the United States.

Revenue expanded from $328.5M in FY2022 to $419.4M in FY2023 and peaked at $464.8M in FY2024, before falling 28.3% to $333.3M in FY2025 and 28.7% to $237.8M in FY2026. Over the five years from FY2021 to FY2026, revenue generated a compound annual growth rate of 2.8%. Gross margin compressed from 43.0% in FY2023 to 34.7% in FY2026. Operating margin shifted from 12.9% in FY2023 to 0.0% in FY2026, and stood at -16.0% on a trailing twelve month basis. Net income deteriorated from $18.8M in FY2023 to -$230.3M in FY2026. In the latest quarter ended June 30, 2026, revenue fell 23.4% year-over-year, while quarterly earnings growth increased 34.4%.

As of June 30, 2026, Bioceres held $12.2M in cash and short-term investments alongside total debt of $236.8M, resulting in net debt of $224.6M. Shareholders' equity was $39.1M, yielding a debt-to-equity ratio of 6.06. Total assets stood at $471.3M, and the current ratio was 0.81. In FY2025, operating cash flow reached $49.9M and capital expenditures were $14.6M, generating free cash flow of $35.3M, while share buybacks totaled $926,899.

Bioceres closed at $0.28 on October 16, 2026, representing a market capitalization of $17.6M and an enterprise value of $249.6M. The stock trades at a forward P/E of 15.0x, above the 13.4x median of its US-listed Basic Materials peers. Its EV to EBITDA multiple is 18.0x, higher than the peer median of 10.5x, while its price-to-sales multiple of 0.1x sits below the peer median of 1.8x. Over the past year, BIOX fell 85.0%, trailing the S&P 500 return of 16.8%. Over five years, the stock dropped 97.9% compared to an 83.0% gain for the S&P 500.

One analyst provides coverage for the next fiscal year. The mean price target is $2.00, which sits 624.6% above the last closing price of $0.28. Consensus estimates project an EPS of -$0.16 for the fiscal year ending June 30, 2026, and an EPS of $0.05 for the next fiscal year, representing expected EPS growth of 117.1%. Revenue growth for the next fiscal year is estimated at 18.1%. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Bioceres Crop Solutions Corp. (BIOX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BIOX income statement, BIOX balance sheet, BIOX key metrics, BIOX analyst forecast, BIOX chart. See the BIOX stock overview for the latest quote and news.